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INTRODUCTION
Atrial fibrillation (AF) is the most common form of heart
arrhythmias. Prevalence is about 1–2% in the general popu-
lation with a tendency to increase in last 50 years. The prev-
alence tends to increase with age from 0.5% in 40–50
year-old patients to 5–17% in 80–85 year-old patients (Go
et al., 2001; Camm et al., 2010; Stewart et al., 2011;
Camm, 2012). The possibility of developing AF at the age
of 55 in the European population is 23.8% for men and
22.2% for women (Heeringa et al., 2006). AF is associated
with greater cardioembolic accident risk, such as cardio-
embolic stroke, left ventricle hypertrophy, chronic heart
failure, which leads to lower quality of life and higher mor-
tality rates (Kirchhof et al., 2007). The use of oral anticoag-
ulants decreases the risk of thromboembolic accidents in
patients with non-valvular AF. To achieve effective cardio-
embolic accident prophylaxis, oral anticoagulants should be
used regularly for prolonged period of time, which for most
patients has proven to be difficult, considering the specific
use of medication and possible side effects. The available
oral anticoagulants in Latvia are the vitamin K antagonist
(VKA) warfarin and target specific oral anticoagulants
(TSOACs) — rivaroxaban, dabigatran and apixsaban.
Atrial fibrillation in one of the major risk factors of cerebral
infarction and contributes to higher morbidity and mortality
compared with non-AF-related strokes. Stroke etiology in
patients with AF varies from 1–20% with a yearly average
of 4.5% and mortality of 30%. Of all deaths associated with
cardioembolism 80% are caused by cerebral infarction
(Menke et al., 2010; Furie et al., 2012).
In 2012, the European society of cardiology (ESC) pub-
lished the guidelines “2012 Focused Update of the ESC
Guidelines for the Management of Atrial Fibrillation” for
treatment of non-valvular atrial fibrillation, which recom-
mended that patients with AF should be evaluated by the
CHA2DS2-VASc score (Table 1). (Lane et al., 2013). Pa-
tients with a CHA2DS2-VASc score of 2 or above should be
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Atrial fibrillation is one of major risk factors of cerebral infarction. The use of oral anticoagulants is
the only evidence-based method of reducing the risk of cardioembolic accidents. The guidelines
of oral anticoagulant admission and usage have been available since 2012. The results of this
study show that of 550 stroke patients that were admitted to Pauls Stradiòð Clinical University
Hospital, Rîga, Latvia, from 1 January 2014 until 1 July 2014, atrial fibrillation was diagnosed in
247 (45%) cases, and of these patients, only 8.5% used oral anticoagulants before the onset of
stroke. Six months after discharge of 111 (44.9%) stroke survivors, five (4.5%) used no secon-
dary prevention medication, 27 (24.3%) used antiplatelet agents, 54 (48.6%) warfarin, and 25
(22.5%) used target specific oral anticoagulants (TSOACs). The mortality rate was significantly
higher in the patient group that used no secondary prevention medication or antiplatelet agents
compared to the patient group that used oral anticoagulants. The use of oral anticoagulants for
primary stroke prevention in Latvia is insufficient. The mortality of cardioembolic stroke in 180
days is very high — 40.4%. Secondary prevention is essential to prevent recurrent cardioembolic
accidents.
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offered anticoagulation. In patients with a CHA2DS2-VASc
score of 1, consider anticoagulation and base any decision
to treat or not treat on patient preference after balancing the
benefits with risks of treatment. As a second step, HAS-
BLED (Table 1) should be used to assess bleeding risk,
with the aim of modifying this risk through addressing indi-
vidual risk factors that can be altered (Lane et al., 2013).
HAS-BLED should not be used to decide whether to offer
anticoagulation in someone with a CHA2DS2-VASc score
of 2 or above, but to consider its use to balance the benefits
of anticoagulation in patients with a CHA2DS2-VASc score
of 1. On a regular basis, and at least once a year, the risk
status of patients with AF should be re-evaluated depending
on change in risk factors (change of age category, new hy-
pertension, etc) (Camm et al., 2012; Hobbs et al., 2012).
The goal of our study was to evaluate the use of oral antico-
agulants for primary and secondary stroke prevention in pa-
tients with atrial fibrillation.
MATERIALS AND METHODS
In the period between 1 January 2014 and 1 July 2014, in
Latvia, 550 stroke patients were treated in the Clinic of
Neurology, Pauls Stradiòð Clinical University Hospital,
Rîga. Atrial fibrillation was diagnosed in 247 (45%) cases.
Patients with haemorrhagic stroke, subarachnoid haemor-
rhage, or valvular AF were excluded from the study. Thus, a
total of 247 patients were included in the data analysis. Av-
erage age of studied patients was 76.3 years, with range
from 37 to 99. Information was collected about the use of
medication. The CHA2DS2-VASc score (Table 1) was cal-
culated before the onset of stroke (Lane et al., 2013).
Modified Rankin’s score (Table 2) was calculated on dis-
charge from the hospital and 180 days after discharge, to as-
sess functional outcome of patients (Sulter et al., 1999).
Stroke survivors who were discharged from hospital were
divided in four groups based on medication that was used
for secondary prevention of stroke. Prescriptions for oral
anticoagulants within a time frame of 180 days after dis-
charge were used to determine therapeutic management for
secondary stroke prevention. Standardised questions were
asked about patient abilities and use of prescribed medica-
tion.
The data were analyzed using Microsoft Excel and SPSS.
Absolute and relative frequencies were calculated based on
cross-tables. Normal distribution of variables was tested us-
ing a Kolmogorov-Smirnof Test.
This study was approved by the local ethical board of Rîga
Stradiòð University, Rîga, Latvia). Verbal consent was
asked when contacting patients or their relatives by phone.
RESULTS
The CDA2DS2-VASc score (n = 247) was determined bef-
ore the onset of stroke using non-parametric tests. The cal-
culated median was 4 and mode was 4.
Antithrombotics use in primary stroke prevention was inap-
propriate. Before the onset of stroke, 127 (51.4%) patients
had not used any antithrombotic medication, 99 (40.1%)
used antiplatelet agents, 20 (8.1%) warfarin, and one (0.4%)
used TSOACs (Fig. 1).
In-hospital mortality was 11% and 219 (89%) patients were
discharged from hospital. In 12 (5.5%) patients no anti-
T a b l e 1
ASSESSMENT OF STROKE (CHA2DS2-VASC) AND BLEEDING
RISK (HAS-BLED) IN ATRIAL FIBRILLATION PATIENTS
CHA2DS2-VASc Score HAS-BLED Score
Congestive heart failure 1 Hypertension (systolic blood
pressure > 160 mm Hg)
1
Hypertension 1 Abnormal renal and liver
function* (1 point each)
1 or 2
Age  75 y 2 Stroke 1
Diabetes mellitus 1 Bleeding tendency/
predisposition*
1
Stroke/TIA/TE 2 Labile INRs (if on warfarin)* 1
Vascular disease (prior MI,
PAD, or aortic plaque)
1 Elderly (eg, age > 65 y) 1
Drugs or alcohol (1 point
each)*
1 or 2
Aged 65 to 74 y 1
Sex category (ie, female sex) 1
Maximum score 9 Maximum score 9
TIA, transient ischemic attack; TE, thromboembolic; INR, international
normalized ratio; MI, myocardial infarction; PAD, peripheral artery dis-
ease.
*Abnormal renal function is classified as the presence of chronic dialysis,
renal transplantation, or serum creatinine  200 mmol/L. Abnormal liver
function is defined as chronic hepatic disease (e.g., cirrhosis) or biochemi-
cal evidence of significant hepatic derangement (bilirubin 2 to 3 times the
upper limit of normal, in association with aspartate aminotransferase/
alanine aminotransferase/alkaline phosphatase 3 times the upper limit nor-
mal, etc), history of bleeding or predisposition (anemia), labile INR (i. e,
time in therapeutic range < 60%), concomitant antiplatelets or nonsteroidal
anti-inflammatory drugs, or excess alcohol (Lane et al., 2013).
T a b l e 2
MODIFIED RANKIN SCALE (MRS)
Level Description
0 No symptoms
1 No significant disability, despite symptoms; able to perform all
usual duties and activities
2 Slight disability; unable to perform all previous activities but able
to look after own affairs without assistance
3 Moderate disability; requires some help, but able to walk without
assistance
4 Moderately severe disability; unable to walk without assistance
and unable to attend to own bodily needs without assistance
5 Severe disability; bedridden, incontinent, and requires constant
nursing care and attention
6 Exitus letalis
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thrombotic therapy was prescribed for secondary prevention
due to contraindications, 78 (25.6%) patients were dis-
charged on antiplatelet agents, 79 (36.1%) on warfarin and
the remaining 50 patients (22.8%) on TSOACs.
The Modified Rankin’s score (mRs) was calculated at the
time of discharge from hospital. A score of 1–3 was consid-
ered a satisfactorily outcome. At time of discharge 123
(49.8%) patients had satisfactory functional outcome (mRs
0–3), 96 (38.9%) had severe disability (mRs 4–5) and 28
(11.7%) had died in hospital. In the period up to 180 days
after discharge, 100 (54.3%) patients had satisfactory out-
come (mRs 0–3), 11 (5.9%) had severe disability (mRs 4–5)
and 73 (39.8%) patients had died (Fig. 2).
The mortality rate in 180 days was as high as 40.4%. The
most common causes of death were somatic complications
due to severe disability and recurrent cardiovascular acci-
dents. The mortality rate after 180 days in patients using no
secondary prevention antithrombotic medication (67%) or
antiplatelet agents (66%) was significantly higher than in
the patient groups using warfarin (20%) or TSOACs (26%)
(p < 0.05).
In the period of 180 days after discharge a change of secon-
dary prophylaxis was documented. In the patient group for
which secondary prophylaxis had not yet started, 75% be-
gan using antiplatelet agents and 25% warfarin. In the pa-
tients who were discharged using antiplatelet agents, 52%
were still using antiplatelet agents, 33% ambulatory started
using warfarin and 15% TSOACs, mainly because of sig-
nificant neurological deficit and age. In the discharged pa-
tient group using warfarin, 5% stopped using any anti-
thrombotic medication, 15% started using antiplatelet
agents, 63% were still using warfarin, and 17% had started
using TSOACs. Patients who changed medication to
TSOACs admitted that they experienced problems control-
ling INR. In the patient group that was discharged using
NOACs, 9% stopped using any antithrombotic medication,
without consulting a professional, 15% started using anti-
platelet agents after consulting with a general practitioner,
38% were still using TSOACs, and 38% changed medica-
tion to warfarin, mainly because of financial aspects (Fig.
3).
Our study showed that 180 days after discharge, of 67 pa-
tients taking VKA, in 70.1% therapeutical anticoagulation
(INR2.0) was observed, 22.4% had subtherapeutic INR (<
2.0) and 7.5% were not controlling INR (Table 3).
DISCUSSION
Primary cardioembolic stroke prevention in Latvia is insuf-
ficient. According to ESC guidelines, oral anticoagulants
should be used if the CHA2DS2-VASc score is 1 for males
and 2 for females. Median CHA2DS2-VASc was 4 and
mode was 4. In our study group, 91.5% patients were using
Fig. 1. The use of antithrombotic medication
in different periods of the study.
Fig. 2. Modified Rankin’s scale at time of
discharge from hospital and 180 days after
discharge.
T a b l e 3
INTERNATIONAL NORMALISED RATIO (INR) IN 67 PATIENTS US-
ING WARFARIN AT 180 DAYS AFTER DISCHARGE
INR n = 67 %
2.0–3.0 47 70.1
< 2.0 15 22.4
not measured 5 7.5
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inadequate medication or were not using any preventive
antithrombotic medication. (Camm et al., 2012). According
to the recent study by Friberg et al. (2015), patients with a
CHA2DS2-VASc score of 1 are not required to use oral an-
ticoagulants. According to European guidelines, women
with a CHA2DS2-VASc score of 1 should not be given
anticoagulation therapy on the basis of their sex alone. The
risk in men and women with a CHA2DS2-VASc score of 1
is considered to be low and this group is not expected to
benefit from anticoagulation therapy. Among men with a
CHA2DS2-VASc score of 1, the annual stroke risk ranged
between 0.5% and 0.7%, which indicates low risk for cere-
bral infarction (Friberg et al., 2015). Overall, oral anticoag-
ulant use was more common among low-risk patients than
among patients with a CHA2DS2-VASc score  3 (Friberg
et al., 2015). European guidelines favour oral anticoagulant
treatment at CHA2DS2-VASc scores of 1. The newly
adapted US guidelines recommend treatment from a score
of 2 and higher, with an option to treat cases with score 1
with oral anticoagulants, antiplatelet agents, or no medica-
tion (Friberg et al., 2015).
In a Canadian study (Gladstone et al., 2009) that included
597 stroke patients with previously diagnosed atrial fibrilla-
tion, 40% used anticoagulants, 30% used antiplatelet agents
and 30% had not used antithrombotic medication before the
onset of stroke. Of those taking warfarin, 75% had a
subtherapeutic internationally accepted normalised ratio
(INR) range (< 2.0) at the time of stroke admission. Only
10% of the patients with acute stroke with known atrial fi-
brillation were assessed with therapeutical anticoagulation
(INR  2.0) at admission. (Gladstone et al., 2009). Our
study did not specify if a patient had previously diagnosed
atrial fibrillation. Our results showed that 51.4% of patients
had not used any antithrombotic medication, 40.1% of pa-
tients used antiplatelet agents, and use of anticoagulants
was significantly less frequent — warfarin in 8.1% of cases
and TSOACs in 0.4% of cases. In both studies, treatment
of more than 90% of patients was inadequate for successful
coagulation. Our study showed that 180 days after discharge
from the neurologic department, treatment of 70.1% of
patients using VKA was considered as resulting in therap-
eutical anticoagulation (INR  2.0), 7.5% were not control-
ling their INR, and 22.4% had subtherapeutic INR (< 2.0).
Of 219 patients discharged from the hospital, in 5.5% anti-
thrombotic medication was not recommended due to contra-
indications, 25.6% were discharged on antiplatelet agents,
36.1% on warfarin, and 22.8% on TSOACs. The reasons
for avoiding oral anticoagulants in 31.1% of cases were se-
vere neurologic deficit, noncompliance of patient or their
relative, increased age and haemorrhagic transformation of
cerebral infarction. A similar study conducted in Germany
included 6261 patients after transistor ischemic attack or
ischemic stroke, who had been diagnosed with atrial fibril-
lation (Tanislav et al., 2014). They reported 45% of patients
had been prescribed oral anticoagulants after discharge. Ac-
cording to our data, oral anticoagulants were prescribed
more frequently (in 58.9% of patients), but even this pro-
portion is insufficient. The use of antiplatelet agents to pre-
vent cerebral infarction in patients with atrial fibrillation has
been documented as ineffective (Camm et al., 2010). Both
studies show that antiplatelet agents are prescribed far too
often in Latvia and in other countries. A German study re-
ported that factors associated with reluctance in prescribing
anticoagulants were increasing age, female sex, treatment at
a non-neurological department, worsening disability, and
dementia (Tanislav et al., 2014).
In the United Kingdom, Moren et al. (2014) embarked on a
retrospective case review of patients with first ever stroke
or TIA, who had possibly preventable or curable disease be-
fore the onset. The study considered four categories of
missed opportunities for stroke/TIA prevention are: un-
treated high blood pressure in patients eligible for treatment
(either blood pressure  160/100 or  140/90 mm Hg in pa-
tients at high cardiovascular disease (CVD) risk); patients
with atrial fibrillation with high stroke risk and no anticoag-
ulant therapy; and no lipid modifying drug therapy pre-
scribed in patients at high CVD risk or with familial hyper-
cholesterolemia (Moren et al., 2014). This study will
Fig. 3. The change of antithrombotic
medication 180 days after discharge
in different patient groups.
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provide adequate data about primary stroke prevention for
patients with AF in the UK, and will identify reasons for not
taking oral anticoagulants in patients with AF.
Some studies suggest that usage of oral anticoagulants for
elderly patients to prevent embolic accidents does not out-
weigh the risk for bleeding (Friberg et al., 2015). In a study
by Lip et al. (2014), 4130 elderly patients in France that
were using VKA were compared to a group of patients who
were not taking any antithrombotic therapy. A conclusion
was made that elderly patients with AF have a higher risk of
stroke and bleeding, but that the benefits of VKA therapy
for stroke/thromboembolism or mortality were present re-
gardless of increasing age. (Lip et al., 2014). In our study,
94 (38%) patients had age 80 years or more. Of these pa-
tients, 11 (11.7%) died in hospital. Of 68 patients contacted,
21 (30.8%) had died in 90 days after leaving hospital and 42
(61.7%) had died within 180 days after discharge.
Of 83 patients discharged, 9 (10.8%) had no preventive
antithrombotic medication prescribed, for 41 (49.3%) pa-
tients antiplatelet agents were prescribed, 18 (21.6%) VKA
and 15 (18.0%) used TSOACs.
In our study in-hospital mortality was 11%, which is rela-
tively high, and mortality at 90 days (27.1%) and 180 days
(54.3%) were very high. High mortality was associated with
severe disability due to stroke, poor compliance using pre-
scribed medication and mistakes in the organization of na-
tional health care. In other European countries, for stroke
patients, in-hospital mortality has been reported to be about
12.1%, the mortality rate at 30 days after onset in Switzer-
land was reported to be 13% (Nedeltchev et al., 2010) and
mortality at 90 days did not exceed 15.7% (Ois et al.,
2007).
In Latvia, primary and secondary prevention of cardio-
embolic stroke is insufficient and mortality in 90 and 180
days after stroke is catastrophically high. It is essential to
raise patient awareness about cardioembolic stroke and its
prevention, and to ensure that physicians prescribe oral anti-
coagulants for patients with atrial fibrillation and high risk
for cerebral infarction, according to published guidelines
(Camm et al., 2012).
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KARDIOEMBOLISKA CEREBRÂLA INFARKTA PRIMÂRÂS UN SEKUNDÂRÂS PROFILAKSES PROBLÇMAS LATVIJÂ
Pçtîjuma mçríis bija izvçrtçt perorâlo antikoagulantu lietoðanu cerebrâlâ infarkta pacientiem ar âtriju fibrilâciju. Âtriju fibrilâcija ir viens no
bieþâkajiem cerebrâla infarkta riska faktoriem. Perorâlo antikoagulantu lietoðana ir vienîgâ uz pierâdîjumiem balstîtâ metode
kardioembolisku notikumu riska samazinâðanai. Perorâlo antikoagulantu nozîmçðanas vadlînijas ir pieejamas kopð 2012. gada, diemþçl
mûsu pçtîjumâ iegûtie dati liecina, ka no 550 pacientiem, kas ârstçti Paula Stradiòa Klîniskajâ universitâtes slimnîcâ Neiroloìijas nodaïâ no
2014. gada 1. janvâra lîdz 2014. gada 1 jûlijam, 247 (45%) diagnosticçta mirdzaritmija. Tikai 8,5% pacientu pirms akûtâ notikuma lietojuði
perorâlos antikoagulantus. Mirstîba stacionârâ bijusi relatîvi augsta — 11%. Savukârt mirstîba 180 dienas pçc izrakstîðanâs no slimnîcas
ðokçjoði augsta — 40,4%. Kâ galvenie nâves iemesli jâmin komplikâcijas dziïâ neiroloìiskâ deficîta dçï un atkârtoti kardioemboliski
notikumi. Seðus mçneðus pçc izrakstîðanâs no stacionâra, izdzîvojuði 111 (44,9%) pacientu, no tiem 5 (4,5%) nelieto nekâdus
antitrombotiskus medikamentus, 27 (24,3%) lieto antiagregantus, 54 (48,6%) vitamîna K antagonistus (warfarin) un 25 (24,3%) jaunos
perorâlos antikoagulantus. Mirstîba bijusi augstâka pacientiem, kuri lietojuði antiagregantus vai nav lietojuði nekâdus antirombotiskus
medikamentus, salîdzinot ar pacientiem, kuri lietojuði perorâlos antikoagulantus. Latvijâ perorâlo antikoagulantu lietoðana primâra insulta
profilaksei ir nepietiekoða. Òemot vçrâ augsto kardioembolisko insultu mirstîbu 180 dienu laikâ, ir nepiecieðams informçt pacientus, kâ arî
medicînas pârstâvjus par ðo saslimðanu, apzinâties riska faktorus un lietot atbilstoðus medikamentus, lai samazinâtu kardioembolisku
notikumu risku.
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